Verge Genomics Will Use Modality.AI in Its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635
VRG50635 is a potential best-in-class small molecule inhibitor of PIKfyve that is in clinical development for amyotrophic lateral sclerosis (ALS) and is expected to move into Phase 1b in the coming months.
- VRG50635 is a potential best-in-class small molecule inhibitor of PIKfyve that is in clinical development for amyotrophic lateral sclerosis (ALS) and is expected to move into Phase 1b in the coming months.
- “Endpoints used in ALS trials are often subjective, biased, and only limited objective biomarkers of neurological function are available.
- The collaboration with Modality.AI builds on Verge’s efforts to enhance how patient data will be collected in its Phase 1b study for VRG50635.
- VRG50635 completed a Phase 1 single- and multiple-ascending dose clinical trial in healthy volunteers in June 2023.